The importance of the disease-free survival (DFS) endpoint to survivors of lung cancer

Bever, Andrea; Manthorne, Jackie; Rahim, Tissa; Moumin, Layla; Johnston, Karissa; Szabo, Shelagh M.

doi:10.1183/13993003.congress-2021.pa2190

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the goal of adjuvant treatment is to increase survival while maintaining quality of life, and a clinical trial does not demonstrate evidence of improved overall survival, a patient may benefit from receiving the treatment at the time of disease recurrence when the motivation for treatment and possible acceptance of certain side effects is stronger ( 76 , 77 ). On the other hand, maintaining patients in a ‘disease-free’ state by prolonging DFS ultimately provides more time living cancer- and cancer symptom-free which can be considered a clinically meaningful goal for patients ( 66 , 78 , 79 ). Only patients who remain ‘on the DFS Kaplan-Meier curve’ have the opportunity to be cured.…”

Section: Adjuvant Treatments In Stage I–iii Egfr-mutated Nsclc and Th...mentioning

confidence: 99%

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives

Kris¹,

Mitsudomi²,

Peters³

2023

Transl Lung Cancer Res

View full text Add to dashboard Cite

Surgical resection followed by adjuvant cisplatin-based chemotherapy is the recommended treatment for patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC). Even with the best management, recurrence is common and increases with disease stage (stage I: 26–45%; stage II: 42–62%; stage III: 70–77%). For patients with metastatic lung cancer and tumours that harbour epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKIs) have improved survival. Their effectiveness in advanced stages of NSCLC raises the possibility that these agents may improve outcomes for patients with resectable EGFR-mutated lung cancer. In the ADAURA study, adjuvant osimertinib provided a significant improvement in disease-free survival (DFS) and reduced central nervous system (CNS) disease recurrence in patients with resected stage IB–IIIA EGFR-mutated NSCLC, with or without prior adjuvant chemotherapy. To reap the maximum benefits of EGFR-TKIs for patients with lung cancer, the early and rapid identification of EGFR mutations [and other oncogenic drivers, such as programmed cell death-ligand 1 (PD-L1), with matched targeted therapies] in diagnostic pathologic specimens has become essential. To ensure patients receive the most appropriate treatment, routine, comprehensive histological, immunohistochemical, and molecular analyses (with multiplex next generation sequencing) should be undertaken at the time of diagnosis. The potential for personalised treatments to cure more patients with early-stage lung cancer can only be realised if all therapies are considered when the care plan is formulated, by the multi-specialty experts managing patients. In this review, we discuss the progress and prospects for adjuvant treatments as part of a comprehensive plan of care for patients with resected stages I–III EGFR-mutated lung cancer, and explore how the field could go beyond DFS and overall survival to make cure a more frequent outcome of treatment in patients with resected EGFR-mutated lung cancer.

show abstract

Section: Adjuvant Treatments In Stage I–iii Egfr-mutated Nsclc and Th...mentioning

confidence: 99%

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives

Kris¹,

Mitsudomi²,

Peters³

2023

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

The importance of the disease-free survival (DFS) endpoint to survivors of lung cancer

Cited by 1 publication

References 0 publications

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives

Contact Info

Product

Resources

About